Faraday Future (FFAI) completes investment in Qualigen Therapeutics

Rhea-AI Filing Summary

Faraday Future Intelligent Electric Inc. filed a current report to note that it has closed an investment in Qualigen Therapeutics, Inc., a company listed on Nasdaq under the symbol QLGN. The closing occurred on September 30, 2025, and was announced the same day in a press release.

The report classifies this as an "Other Events" disclosure and includes the press release as an exhibit. No financial terms or strategic details of the investment are described in the excerpt, but the filing confirms that the transaction has been completed rather than merely planned.

false 0001805521 0001805521 2025-09-30 2025-09-30 0001805521 FFAI:ClassCommonStockParValue0.0001PerShareMember 2025-09-30 2025-09-30 0001805521 FFAI:RedeemableWarrantsExercisableForSharesOfClassCommonStockAtExercisePriceOf110400.00PerShareMember 2025-09-30 2025-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): September 30, 2025

Faraday Future Intelligent Electric Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-39395		84-4720320
(State or other jurisdiction		(Commission File Number)		(I.R.S. Employer
of incorporation)				Identification No.)

18455 S. Figueroa Street
Gardena, CA		90248
(Address of principal executive offices)		(Zip Code)

(424) 276-7616 

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A common stock, par value $0.0001 per share		FFAI		The Nasdaq Stock Market LLC
Redeemable warrants, exercisable for shares of Class A common stock at an exercise price of $110,400.00 per share		FFAIW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On September 30, 2025, Faraday Future Intelligent Electric Inc. issued a press release announcing the closing of its investment in Qualigen Therapeutics, Inc. (NASDAQ: QLGN).

The information contained in this Current Report on Form 8-K, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release dated September 30, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 30, 2025

	FARADAY FUTURE INTELLIGENT ELECTRIC INC.
	By:	/s/ Koti Meka
	Name:	Koti Meka
	Title:	Chief Financial Officer

2

FAQ

What did Faraday Future Intelligent Electric Inc. (FFAI) disclose in this 8-K?

Faraday Future Intelligent Electric Inc. disclosed that it closed an investment in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) and announced this transaction via a press release dated September 30, 2025.

When did FFAI close its investment in Qualigen Therapeutics?

The investment in Qualigen Therapeutics, Inc. closed on September 30, 2025, which is also the date of the related press release.

Does the FFAI 8-K provide financial terms of the Qualigen investment?

The excerpt indicates that Faraday Future issued a press release about the closing of its investment in Qualigen Therapeutics, but it does not include specific financial terms or sizing of the transaction.

How is the Qualigen investment information treated for securities law purposes?

The information about the Qualigen investment, including Exhibit 99.1, is stated as being furnished rather than filed under Section 18 of the Exchange Act and is not automatically incorporated by reference into other securities filings.

What exhibits are attached to this FFAI 8-K filing?

The filing lists Exhibit 99.1, a press release dated September 30, 2025, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.

Who signed the FFAI 8-K related to the Qualigen investment?

The report was signed on behalf of Faraday Future Intelligent Electric Inc. by Koti Meka, the company’s Chief Financial Officer, dated September 30, 2025.